Vanguard Group
EVMN

Vanguard Group’s Evommune Inc EVMN Stock Holding History

Vanguard Group’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.6M Buy
+502,574
New +$9.44M ﹤0.01% 3035

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group's EVMN Position: Q4 2025 in Review

Vanguard Group opened a new position in Evommune Inc (EVMN) in Q4 2025: 502,574 shares worth $8.6M. The stake represents ﹤0.01% of the portfolio and ranks #3035 among its holdings.

59 funds tracked by Wall St. Rank hold EVMN as of Q4 2025.

  • Vanguard Group held 502,574 shares of Evommune Inc worth $8.6M as of Q4 2025.
  • Evommune Inc was a new Vanguard Group position in Q4 2025.
  • Evommune Inc made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3035 holding.
  • 59 funds tracked by Wall St. Rank held Evommune Inc as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.